IL311624A - Methods for treating hair loss disorders with TYK2 inhibitors - Google Patents
Methods for treating hair loss disorders with TYK2 inhibitorsInfo
- Publication number
- IL311624A IL311624A IL311624A IL31162424A IL311624A IL 311624 A IL311624 A IL 311624A IL 311624 A IL311624 A IL 311624A IL 31162424 A IL31162424 A IL 31162424A IL 311624 A IL311624 A IL 311624A
- Authority
- IL
- Israel
- Prior art keywords
- formula
- hair
- tyk2
- compound
- treated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163247672P | 2021-09-23 | 2021-09-23 | |
| PCT/US2022/044346 WO2023049241A1 (en) | 2021-09-23 | 2022-09-22 | Methods of treating hair-loss disorders with tyk2 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL311624A true IL311624A (en) | 2024-05-01 |
Family
ID=83899658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL311624A IL311624A (en) | 2021-09-23 | 2022-09-22 | Methods for treating hair loss disorders with TYK2 inhibitors |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240390372A1 (https=) |
| EP (1) | EP4404930A1 (https=) |
| JP (1) | JP2024533700A (https=) |
| KR (1) | KR20240065283A (https=) |
| CN (2) | CN118251222A (https=) |
| AU (1) | AU2022350509A1 (https=) |
| CA (1) | CA3232812A1 (https=) |
| IL (1) | IL311624A (https=) |
| MX (1) | MX2024003510A (https=) |
| WO (1) | WO2023049241A1 (https=) |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3495358T (lt) | 2012-11-08 | 2022-05-25 | Bristol-Myers Squibb Company | Amidais pakeisti heterocikliniai junginiai, naudingi kaip il-12, il-23 ir (arba) ifn alfa atsako moduliatoriai |
| TWI582077B (zh) * | 2013-11-07 | 2017-05-11 | 必治妥美雅史谷比公司 | 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物 |
| TW202515876A (zh) * | 2017-03-08 | 2025-04-16 | 日商武田藥品工業股份有限公司 | Tyk2抑制劑及其用途 |
| JP7113023B2 (ja) * | 2017-03-30 | 2022-08-04 | ブリストル－マイヤーズ スクイブ カンパニー | ６－（シクロプロパンアミド）－４－（（２－メトキシ－３－（１－メチル－１ｈ－１，２，４－トリアゾール－３－イル）フェニル）アミノ）－ｎ－（メチル－ｄ３）ピリダジン－３－カルボキシアミドの製造方法 |
| KR102848769B1 (ko) | 2018-05-31 | 2025-08-20 | 브리스톨-마이어스 스큅 컴퍼니 | 6-(시클로프로판카르복스아미도)-4-((2-메톡시-3-(1-메틸-1h-1,2,4-트리아졸-3-일)페닐)아미노)-n-(메틸-d3) 피리다진-3-카르복스아미드의 결정질 형태 |
| US20230093099A1 (en) * | 2019-04-02 | 2023-03-23 | Cullgen (Shanghai), Inc. | Compounds and methods of treating cancers |
| US11357775B2 (en) * | 2019-04-30 | 2022-06-14 | Celgene Corporation | Combination therapies comprising apremilast and Tyk2 inhibitors |
| SG11202112043PA (en) * | 2019-04-30 | 2021-11-29 | Celgene Corp | Combination therapies comprising apremilast and tyk2 inhibitors |
| US12570637B2 (en) | 2019-06-12 | 2026-03-10 | Bristol-Myers Squibb Company | Crystalline salt forms 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyld3) pyridazine-3-carboxamide |
| JP7812785B2 (ja) | 2019-09-18 | 2026-02-10 | ブリストル－マイヤーズ スクイブ カンパニー | Ｔｙｋ２阻害薬の剤形 |
| AU2021205465A1 (en) * | 2020-01-06 | 2022-07-14 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
| CN111704617B (zh) * | 2020-06-15 | 2022-08-23 | 嘉兴特科罗生物科技有限公司 | 一种小分子化合物 |
| CN112142675B (zh) * | 2020-10-09 | 2021-11-30 | 嘉兴特科罗生物科技有限公司 | 一种作为jak激酶抑制剂的小分子化合物及其用途 |
-
2022
- 2022-09-22 EP EP22792963.5A patent/EP4404930A1/en active Pending
- 2022-09-22 JP JP2024518606A patent/JP2024533700A/ja active Pending
- 2022-09-22 CN CN202280075809.3A patent/CN118251222A/zh active Pending
- 2022-09-22 KR KR1020247012854A patent/KR20240065283A/ko active Pending
- 2022-09-22 AU AU2022350509A patent/AU2022350509A1/en active Pending
- 2022-09-22 CN CN202411332236.5A patent/CN119345364A/zh active Pending
- 2022-09-22 CA CA3232812A patent/CA3232812A1/en active Pending
- 2022-09-22 MX MX2024003510A patent/MX2024003510A/es unknown
- 2022-09-22 US US18/694,424 patent/US20240390372A1/en active Pending
- 2022-09-22 WO PCT/US2022/044346 patent/WO2023049241A1/en not_active Ceased
- 2022-09-22 IL IL311624A patent/IL311624A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240065283A (ko) | 2024-05-14 |
| CA3232812A1 (en) | 2023-03-30 |
| JP2024533700A (ja) | 2024-09-12 |
| EP4404930A1 (en) | 2024-07-31 |
| US20240390372A1 (en) | 2024-11-28 |
| AU2022350509A1 (en) | 2024-04-04 |
| MX2024003510A (es) | 2024-04-09 |
| WO2023049241A1 (en) | 2023-03-30 |
| CN118251222A (zh) | 2024-06-25 |
| CN119345364A (zh) | 2025-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhao et al. | Anti‐aging pharmacology in cutaneous wound healing: effects of metformin, resveratrol, and rapamycin by local application | |
| Zhuang et al. | Induction of M2 macrophages prevents bone loss in murine periodontitis models | |
| Guicciardi et al. | Macrophages contribute to the pathogenesis of sclerosing cholangitis in mice | |
| Lie et al. | Low dose Naltrexone for induction of remission in inflammatory bowel disease patients | |
| Milenkovic et al. | P2Y receptor-mediated stimulation of Muller glial cell DNA synthesis: dependence on EGF and PDGF receptor transactivation | |
| Weinblatt et al. | Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve‐week, randomized, placebo‐controlled trial | |
| Yang et al. | Coordinate regulation of TPL-2 and NF-κB signaling in macrophages by NF-κB1 p105 | |
| Hughes et al. | Testosterone enables growth and hypertrophy in fusion impaired myoblasts that display myotube atrophy: deciphering the role of androgen and IGF-I receptors | |
| Aversa et al. | β-Hydroxy-β-methylbutyrate (HMB) prevents dexamethasone-induced myotube atrophy | |
| van Steensel et al. | Imatinib mesylate and AMN107 inhibit PDGF-signaling in orbital fibroblasts: a potential treatment for Graves’ ophthalmopathy | |
| Lin et al. | Heme oxygenase‐1 directly binds STAT 3 to control the generation of pathogenic Th17 cells during neutrophilic airway inflammation | |
| Cutolo et al. | Nintedanib downregulates the transition of cultured systemic sclerosis fibrocytes into myofibroblasts and their pro-fibrotic activity | |
| Karmouty‐Quintana et al. | The antifibrotic effect of A2B adenosine receptor antagonism in a mouse model of dermal fibrosis | |
| Herrmann et al. | Olodaterol shows anti‐fibrotic efficacy in in vitro and in vivo models of pulmonary fibrosis | |
| Huang et al. | M2‐like macrophages polarized by Foxp3− Treg‐of‐B cells ameliorate imiquimod‐induced psoriasis | |
| Lai et al. | Novel approach to alleviate lupus nephritis: targeting the NLRP3 inflammasome in CD8+ CD69+ CD103+ TRM cells | |
| Rutkowski et al. | Epidermal growth factor receptor/mitogen-activated kinase inhibitor treatment induces a distinct inflammatory hair follicle response that includes collapse of immune privilege | |
| Rip et al. | Bruton's tyrosine kinase inhibition induces rewiring of proximal and distal B‐cell receptor signaling in mice | |
| Zhang et al. | CCN1 upregulates IL‐36 via AKT/NF‐κB and ERK/CEBP β‐mediated signaling pathways in psoriasis‐like models | |
| Leung et al. | A review of spatial transcriptomics in psoriasis: new insights into cellular contributions | |
| US20240390372A1 (en) | Methods of treating hair-loss disorders with tyk2 inhibitors | |
| Tada et al. | Partial suppression of M1 microglia by Janus kinase 2 inhibitor does not protect against neurodegeneration in animal models of amyotrophic lateral sclerosis | |
| Karaś et al. | The cyclin‐dependent kinase inhibitor AT7519 is a human RORγt agonist | |
| Kanbe et al. | Inhibition of JNK in synovium by treatment with golimumab in rheumatoid arthritis | |
| Valent et al. | Diagnosis and treatment of anaphylaxis in patients with mastocytosis |